# Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

> **NCT00006246** · PHASE1 · COMPLETED · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 28 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Leukemia
- Lymphoma
- Metastatic Cancer
- Retinoblastoma
- Sarcoma

## Interventions

- **DRUG:** busulfan

## Key facts

- **NCT ID:** NCT00006246
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2003-05
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2009-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006246, "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*